Medexus Pharmaceuticals (TSE:MDP) Hits New 52-Week High – What’s Next?

Shares of Medexus Pharmaceuticals Inc. (TSE:MDP) reached a new 52-week high on Thursday . The stock traded as high as C$3.83 and last traded at C$3.84, with a volume of 84289 shares trading hands. The stock had previously closed at C$3.60.

Analyst Ratings Changes

Several research analysts have issued reports on MDP shares. Raymond James upgraded shares of Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 target price on the stock in a report on Wednesday. Leede Financial set a C$8.25 price objective on shares of Medexus Pharmaceuticals and gave the stock a “speculative buy” rating in a research note on Monday, September 30th. Finally, Alliance Global Partners upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a report on Monday, December 23rd. Two investment analysts have rated the stock with a buy rating and four have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Strong Buy” and an average target price of C$5.25.

Medexus Pharmaceuticals Stock Performance

The company has a 50 day moving average of C$2.74 and a two-hundred day moving average of C$2.52. The stock has a market cap of C$94.20 million, a PE ratio of 76.80 and a beta of 1.96.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.